The study also provides in vivo evidence that i.v. injection of Nec‐1 before the onset of AD‐like phenotypes significantly reduces Aβ oligomers, plaques and hyperphosphorylated tau in the cortex and hippocampus, alters apoptotic marker protein expression levels and inhibits cognitive impairments in AD mouse models. The gene discussed is MAPT; the disease is Alzheimer disease.